Table 2.
Literature review.
| Author, Year | No. of pt | Med Age (mths) | Sex | HTN at Dx (%) | Meta (%) | Preop CT | No CT Response (Hist Type) | Surgery Type | + Margins after NSS (% Kidneys) | RTx (Postop) | Postop CT | ESKD (%) | NB | Outcome | OS % | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | Yes | No | bNSS | uTN | uTN + uNSS | uNSS | bTN | Yes (%) | No | Relapse | Death | |||||||||||
| Aydin, 2019 [30] | 30 | 21.7 | 13 | 17 | NA | 3 (10) | 30 | 0 | 7 (4 CPDN/ET, 3 DA) | 6 | 3 | 19 | 1 | 1 | 3/32 (9) | 4 * 6 |
NA | 1 (3.3) | 6 (20) | 24 | NA | NA | 86 (10y) |
| Doganis, 2019 [31] | 21 | 3.1 y | 11 | 10 | NA | 0 | 21 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 4 (19) | 17 | 3 | 4 | 76.3 (5y) |
| Saha, 2019 [32] | 6 | 2 y | 2 | 4 | NA | 0 | 6 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | NA | NA | NA | 0 | NA | NA | 2 | 0 | 90 (2–5y) |
| Tan, 2018 [33] | 18 | 2.28 y | 10 | 8 | NA | NA | 18 | 0 | NA | 16 | 0 | 2 | 0 | 0 | 1/34 (3) | NA | NA | 0 | NA | NA | 2 | 2 | 85.56 (4y) |
| Ehrlich, 2017 [7] | 189 | NA | NA | NA | NA | 27 (14) | 189 | 0 | 60 (NA) | 66 | 20 | 90 | 8 | 5 | NA | NA | NA | NA | NA | NA | 23 | 1 | 94.9 (4y) |
| Chen, 2016 [34] | 7 | 12 | 3 | 4 | NA | NA | 5 | 2 | NA | 0 | 5 | 2 | 0 | 0 | NA | 3 | 7 | 2 (29) | 2 (29) | 5 | 2 | 0 | NA |
| Davidoff, 2015 [35] | 42 | 2.2 y | 19 | 23 | NA | 7 (17) | 42 | 0 | NA | 39 | 0 | 3 | 0 | 0 | NA | 18 | 40 | 0 | NA | NA | 7 | 6 | 85.7 (3y) |
| Agarwala, 2014 [36] | 11 | 6–30 | 8 | 3 | NA | 3 (27) | 11 | 0 | NA | 7 | 0 | 3 | 0 | 0 | NA | 6 | 10 | 1 (9.1) | NA | NA | 5 | 1 | 90 (5y) |
| Hubertus, 2015 [37] | 22 | 39.4 | 10 | 12 | NA | 4 (18) | 21 | 1 | NA | 10 | 0 | 12 | 0 | 0 | NA | 3 | NA | NA | 17 (85) | 5 | 3 | 2 | NA |
| Furtwängler, 2014 [24] | 136 | 2.5 y | NA | NA | NA | 19 (14) | 104 | 17 | 13 (NA) | 43 | 15 | 33 | 11 | 0 | 30% | 16 | 116 | NA | NA | NA | 27 | 20 | NA |
| Oue, 2014 [38] | 31 | 15.5 | 16 | 15 | NA | 2 (6) | 24 | 7 | 3 (NA) | 10 | 0 | 15 | 0 | 3 | NA | 3 *1 |
NA | 4 (16) | NA | NA | 3 | 2 | 92.6 (5y) |
| Hadley, 2013 [39] | 20 | 2.5 y | 11 | 9 | NA | 4 (20) | 20 | 0 | NA | NA | NA | NA | NA | NA | 3/22 (14) | 13 | NA | 2 (10) | NA | NA | 2 | 3 | 85 (2y) |
| Indolfi, 2013 [27] | 93 | 24 | 32 | 61 | NA | 11 (12) | 81 | 6 | NA | 35 | 17 | 31 | 5 | 1 | NA | 20 | NA | NA | 6 (6) | 85 | 27 | 17 | 80 |
| Sulkowski, 2012 [40] | 12 | 17 | 4 | 8 | NA | 1 (8) | 10 | 2 | NA | 6 | 0 | 5 | 1 | 0 | NA | 3 | NA | 0 | NA | NA | 0 | 0 | NA |
| Sudour, 2012 [28] | 49 | 2.3 y | 18 | 31 | 10 (20) | 5 (10) | 49 | 0 | 11 (10 ST, 1 DA) | 19 | 0 | 29 | 0 | 1 | NA | 11 | 44 | 7 (14.3) | NA | NA | 7 | 5 | 89.5 (5y) |
| Halim, 2012 [41] | 25 | 34.5 (m) | 9 | 16 | 6 (24) | 2 (8) | 25 | 0 | 6 (not ST) | 2 | 3 | 13 | 0 | 0 | NA | 3 | NA | 0 | NA | NA | 5 | 9 | 74 (3y) |
| Millar, 2011 [42] | 23 | 2.29 y | 8 | 15 | 12 (52) | 1 (4) | 22 | 1 | NA | NA | NA | NA | NA | NA | NA | 2 | NA | NA | 19 (83) | 4 | 7 | 11 | 55.6 (5y) |
| Hamilton, 2011 [25] | 188 | 32 | 74 | 114 | NA | 16 (18) | 105 | 83 | 1 (NA) | 64 | 6 | 104 | 8 | 6 | NA | 64 | NA | 23 (12) | 58 (31) | 130 | 54 | NA | 84 (8y) |
| Weirich, 2004 [43] | 28 | 1.9 y | NA | NA | NA | 3 (11) | 28 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 15 (54) | NA | NA | 5 | 4 | NA |
| Kubiak, 2004 [44] | 23 | 19 | 7 | 16 | 9 (39) | 4 (17) | 18 | 5 | 15 (NA) | 5 | 0 | 18 | 0 | 0 | 8/28 (29) | NA | NA | 2 (9) | 8(35) | 15 | NA | 6 | NA |
| Cooper, 2000 [45] | 23 | 30.6 (m) | 8 | 15 | NA | NA | 21 | 2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 9 | 10 | NA |
| Fuchs, 1999 [46] | 14 | 22 | 2 | 12 | NA | 0 | 11 | 1 | 6 (NA) | 9 | 1 | 4 | 0 | 0 | NA | NA | NA | 0 | NA | NA | 1 | 1 | NA |
| Kullendorff, 1999 [47] | 6 | 2.4 y (m) | 1 | 5 | NA | NA | 6 | 1 | 1 (NA) | 3 | 2 | 0 | 0 | 0 | NA | 2 | 1 | NA | 2 (33) | 5 | 1 | 2 | NA |
| Nawaz, 1999 [48] | 7 | 3 y (m) | 5 | 2 | NA | NA | 5 | 2 | 0 | 3 | 1 | 1 | 0 | 0 | NA | 2 | 5 | NA | NA | NA | 1 | 3 | NA |
| Tomlinson 1999 [49] | 8 | 1.1 y | 3 | 5 | NA | 1 | 7 | 1 | NA | 1 | 3 | 2 | 2 | 0 | 0/8 | 1 | 8 | 0 | 6 (75) | 2 | 0 | 2 | NA |
| Kumar, 1998 [50] | 70 | 24.4 (m) | 28 | 42 | 32 (45) | 9 (13) | 57 | 13 | 34 (NA) | 11 | 10 | 30 | 4 | 6 | NA | 21 | NA | 3 (4) | 22 (31) | 48 | NA | 22 | NA |
| Alfer, 1993 [51] | 14 | 37 | 2 | 12 | NA | 0 | 14 | 0 | NA | 8 | 0 | 5 | 0 | 0 | 5/11 (45) | 2 *2 |
NA | NA | 6 (43) | 2 | 4 | 3 | NA |
| Shearer, 1993 [52] | 36 | 27 | 13 | 16 | NA | 4 (11) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1 (3) | 22 (61) | 8 | NA | 4 | 64 (5y) |
| Montgomery, 1991 [26] | 185 | 2.1 y (m) | 80 | 105 | NA | 35 (19) | 185 | 0 | NA | NA | NA | NA | NA | NA | NA | 101 | NA | 10 (5) | NA | NA | NA | 51 | 73 (5y) |
| Coppes, 1989 [53] | 67 | 20.2 | 26 | 41 | NA | 5 (7) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 24 | 64 (?y) |
| Hanash 1987 [54] | 6 | NA | 3 | 3 | NA | NA | NA | NA | NA | 1 | 3 | 2 | 0 | 0 | NA | 1 | 6 | NA | 2 (33) | 4 | 0 | 2 | NA |
| Cohen, 1986 [55] | 22 | 30 | 13 | 9 | NA | 4 (18) | NA | NA | NA | 5 | 7 | 8 | 0 | 0 | NA | 18 | 20 | 2 (9) | 9 (56) | 7 | NA | 7 | NA |
| Asch, 1985 [56] | 21 | 28.8 (m) | 6 | 15 | 4 (19) | 3 (14) | NA | NA | NA | 6 | 1 | 10 | 0 | 4 | NA | 11 | NA | NA | NA | NA | 3 | 9 | 57 (?y) |
| Wikström, 1982 [57] | 6 | 12 | 6 | 0 | 1 (17) | NA | NA | NA | NA | 2 | 2 | 2 | 0 | 0 | NA | 5 | NA | NA | NA | NA | 0 | 4 | NA |
| Wasiljew, 1982 [58] | 14 | 14.5 | 4 | 10 | NA | NA | NA | NA | NA | 3 | 4 | 7 | 0 | 0 | NA | 10 | 11 | NA | NA | NA | 2 | 5 | NA |
| Jones, 1982 [59] | 18 | 16 | NA | NA | NA | 4 (22) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1 | 13 (72) | 5 | 9 | 11 | NA |
| Current cohort, 2021 | 23 | 31.5 | 11 | 12 | 16 (69.6) | 4 (17) | 23 | 0 | 6 (5 ST-WT, 1 DA) | 6 | 4 | 9 | 6 | 1 | 2/15 | 7 | 23 | 2 (8.7) | 21 (97.3) | 2 | 0 | 2 | NA |
| TOTAL | 1491 | 12–39.4 | 466 | 670 | 80/240 (33.3%) | 181/1409 (12.8%) | 88.7% | 11% | 163/1307 (20.9%) | 358 | 158 | 408 | 46 | 28 | 3–45% | - | 359/1054 (34.1%) | 3–54% | 6–97.3% | 18.2% | 19.7% | ||
No.: number; pt: patients; Med: median; mths: months; M: male; F: female; HTN: hypertension; Dx: diagnosis; preop: preoperative; CT: chemotherapy; hist: histological; bNSS: bilateral nephron-sparing surgery; uTN: unilateral tumornephrectomy; uNSS: unilateral nephron-sparing surgery; bTN: bilateral tumornephrectomy; +: positive; RTx: radiotherapy; postop: postoperative; ESKD: end-stage kidney disease; NB: nephroblastomatosis; OS: overall survival; NA: not available; CPDN: cystic partially differentiated nephroblastoma; ET: epithelial type; DA: diffuse anaplasia; *: preoperative radiotherapy; ST: stromal type; y: years; (m): mean; ?: unknown number of years.